1. Introduction {#sec1-ijerph-17-04027}
===============

Chronic obstructive pulmonary disease (COPD) prevalence is increasing over time. It is the fourth leading cause of death in the world and it will be the third by 2021. COPD exacerbations are episodes of temporary symptom worsening (e.g., breathlessness, cough, sputum production) that carry significant consequences for patients \[[@B1-ijerph-17-04027],[@B2-ijerph-17-04027]\] Additionally, exacerbations are associated with an accelerated rate of lung function decline, reduced quality of life, and an increased mortality risk \[[@B3-ijerph-17-04027]\]. COPD exacerbations are heterogeneous and dependent on multiple risk factors \[[@B4-ijerph-17-04027]\]; however, generally, their frequency and severity increase as the disease worsens \[[@B5-ijerph-17-04027]\].

The fact that COPD exacerbations can be associated with influenza is of great public health interest. The most frequent causes of exacerbations are respiratory infections, most of them viral. In particular, influenza can be a causative virus for exacerbations, of which the more severe ones result in hospital admissions and even death \[[@B6-ijerph-17-04027],[@B7-ijerph-17-04027]\]. Two systematic reviews recently analyzed the effectiveness of seasonal influenza vaccination in patients with COPD, concluding that the evidence supports a positive benefit--risk ratio for seasonal influenza vaccination in these patients, although most of the included trials were more than a decade old \[[@B8-ijerph-17-04027],[@B9-ijerph-17-04027]\]. Considering the role of influenza in contributing to COPD exacerbations, the associated complications, and their related healthcare costs, immunization against influenza is recommended for all patients with COPD by major agencies and guidelines \[[@B1-ijerph-17-04027],[@B10-ijerph-17-04027],[@B11-ijerph-17-04027]\].

Despite influenza vaccination being recommended, vaccination rates are highly variable among different countries, including Spain \[[@B12-ijerph-17-04027],[@B13-ijerph-17-04027],[@B14-ijerph-17-04027],[@B15-ijerph-17-04027],[@B16-ijerph-17-04027],[@B17-ijerph-17-04027]\], with further room for improvement \[[@B18-ijerph-17-04027]\]. On the one hand, those COPD patients who are likely to exacerbate could have more motivation to accept influenza vaccination \[[@B16-ijerph-17-04027],[@B17-ijerph-17-04027]\]. On the other hand, vaccination rejection among COPD patients has been attributed to concerns about increased exacerbations or adverse reactions caused by the vaccine itself \[[@B13-ijerph-17-04027],[@B16-ijerph-17-04027]\]. There are also many knowledge gaps regarding the impact of COPD severity and co-morbidity on influenza vaccine effectiveness. Therefore, additional studies are required \[[@B6-ijerph-17-04027],[@B9-ijerph-17-04027]\].

Our primary aim is to determine the prevalence of influenza vaccination in COPD patients in a real-life population cohort in the Balearic Islands (Spain) and the association between history of influenza vaccination and COPD exacerbations.

2. Materials and Methods {#sec2-ijerph-17-04027}
========================

Study design: Retrospective cohort study analyzing real-life data from the COPD population of the MAJOrca Real-world Investigation in COPD and Asthma cohort (MAJORICA-cohort). We reported our findings in line with Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for observational studies using routinely collected health data \[[@B19-ijerph-17-04027]\].

Data source: The MAJORICA-cohort contains data from all patients (≥18 years) with a primary care diagnosis of asthma and/or COPD in 2012 (*N* = 68,578), irrespective of health insurance, with at least two years follow-up available. Most recent follow-up data are from 2015. The cohort data are anonymously collected from the unique primary care system (eSIAP), all hospital systems, as well as the electronic prescription system (RELE) in the Balearic Islands, Spain \[[@B20-ijerph-17-04027],[@B21-ijerph-17-04027],[@B22-ijerph-17-04027]\].

Study population: Among the overall MAJORICA-cohort, patients who were using respiratory medication (ATC (Anatomical Therapeutic Chemical) code: R03) in 2012, 2013, and 2014 were firstly selected. From the included sample, all patients who had a physician diagnosis of COPD (ICD-9 codes: 491, 492, and/or 496) and were over 40 years of age were identified as patients with actively treated COPD.

Exposure: Patients were classified in two cohorts (exposed versus non-exposed) according to whether or not they had received influenza vaccination in the 2012--2013 campaign (between 18 October and 30 November 2012).

Outcome: The outcome of interest was COPD exacerbation. COPD exacerbation was defined as any episode involving an increase in patient's baseline COPD symptoms (cough, pleghms, and/or dyspnea), requiring the prescription of an antibiotic and/or systemic corticosteroid (moderate exacerbation), or hospital admission for more than 24 h (severe exacerbation) \[[@B23-ijerph-17-04027],[@B24-ijerph-17-04027]\]. The total frequency of exacerbations (moderate and severe) was quantified in 2012 and 2013. In a sensitivity analysis, exacerbations that occurred during the 2013 influenza epidemic seasonal period in our setting (7 January 2013 to 31 March 2013) \[[@B25-ijerph-17-04027]\] were also identified and quantified as a specific variable. In order to differentiate a new exacerbation from a previous treatment failure, each exacerbation had to be separated for at least 6 weeks from previous exacerbation initial treatment or 4 weeks from hospital discharge.

Co-variates: At baseline, for each patient, sociodemographic and clinical characteristics were collected, including sex, age, smoking habit, COPD obstruction severity (by GOLD grades 1--4), relevant comorbidities, respiratory treatments, and number and severity of COPD exacerbations in the previous year in order to identify the exacerbation "phenotype". "Exacerbator phenotype" was defined as a patient who suffered from at least two moderate exacerbations or one severe exacerbation in a one-year period according to the main national and international guidelines definition \[[@B1-ijerph-17-04027],[@B16-ijerph-17-04027],[@B23-ijerph-17-04027],[@B26-ijerph-17-04027]\]. "Non-exacerbator phenotype" patients were those having ≤1 moderate exacerbation and no severe exacerbations in a one-year period.

Statistical analyses: For categorical and discrete variables, proportions were estimated using Pearson's Chi-squared tests for comparisons or Fisher's exact tests when necessary. Quantitative variables were expressed as mean and standard deviation (SD) using the student's *t*-test for comparisons after normal distribution was confirmed using the Shapiro--Wilk test. Dichotomous values ("at least one admission for COPD exacerbation", "at least one moderate COPD exacerbation", and "exacerbator phenotype or not" during the following year) were treated as dependent (effect) variables. To assess the crude univariate association between influenza vaccination and the risk of COPD exacerbations, crude odds ratios (OR) were estimated using unconditional logistic regression with 95% confidence intervals (95% CI). Non-vaccinated COPD patients were the reference category. Thus, an OR greater than one indicates that the vaccine is a risk factor for exacerbations. An OR less than one indicates that vaccination is protective, and an OR equal to one indicates a null effect on the risk of exacerbations the following year. To control for confounding bias, we predefined confounders related with the exposure (vaccination) and/or the outcome (exacerbations) in a stepwise regression analysis. The co-variables finally included were age (continuous variable), gender, concomitant asthma diagnosis, COPD severity (GOLD grades 1--4), smoking status (ordinal variable: non-smoker, former smoker, current smoker), number of moderate exacerbations in the previous year, number of severe exacerbations in the previous year, and the following comorbidities: heart failure, atrial fibrillation, cor pulmonale, anxiety, osteoporosis, allergic rhinitis, gastroesophageal reflux disease, and diabetes. Associations were stratified according to COPD severity based on forced expiratory volume in one second (FEV~1~%) predicted (GOLD grades 1--4) and restricted to patients with spirometry confirmed COPD (FEV~1~/FVC (Forced Vital Capacity) \< 0.7) in a sensitivity analysis. We set the alpha error at 0.05, and all *p*-values were bilateral. All statistical analyses were performed using IBM SPSS Statistics, version 22.0 (IBM, New York, NY, USA).

Ethics: The study protocol PI17-07 was approved by the Primary Care Research Committee of Mallorca. All data came from real-life clinical files, but they were anonymized for analysis, making it impossible to identify individual patients.

3. Results {#sec3-ijerph-17-04027}
==========

3.1. Population Characteristics {#sec3dot1-ijerph-17-04027}
-------------------------------

The flow chart for selecting study patients is shown in [Figure 1](#ijerph-17-04027-f001){ref-type="fig"} (R03 = respiratory medication).

In total, 12,396 patients fulfilled all study inclusion/exclusion criteria. Most patients were men (67.3%), overall mean age was 69.7 years, almost one third were current smokers, mean FEV~1~ (% predicted) was 62.7, and 24% were frequent exacerbators. Patients' sociodemographic and clinical variables are shown in [Table 1](#ijerph-17-04027-t001){ref-type="table"}.

3.2. Prevalence and Characteristics of Influenza Vaccination {#sec3dot2-ijerph-17-04027}
------------------------------------------------------------

Overall, the influenza vaccination coverage in COPD patients was 59.6% (7393/12396). A comparison between vaccinated and non-vaccinated patients is presented in [Table 1](#ijerph-17-04027-t001){ref-type="table"}. The vaccination rate was slightly higher in men (62.6%) than women (53.6%), and vaccinated subjects were older than those non-vaccinated (71.9 versus 66.6 years, *p* \< 0.001). There were also statistically significant differences in vaccination coverage as a function of BMI or smoking habit. Vaccination rates were slightly higher in more severe COPD patients (65.0% in GOLD 4) in comparison with milder obstructive ones (57.5% in GOLD 1). Vaccination coverage was also higher in patients with a history of moderate and/or severe exacerbations in 2012 (the same year of vaccination) compared to those with no exacerbations during the previous year. Suffering from each of the analyzed comorbidities was also associated with higher influenza vaccination coverage ([Table 1](#ijerph-17-04027-t001){ref-type="table"}). Main comorbidities in relation to influenza vaccination are described in [Supplementary Table S1](#app1-ijerph-17-04027){ref-type="app"}.

3.3. Effects of Influenza Vaccination on COPD Exacerbations {#sec3dot3-ijerph-17-04027}
-----------------------------------------------------------

[Table 2](#ijerph-17-04027-t002){ref-type="table"} shows a descriptive analysis of the history of exacerbations (primary effect endpoint) during the following year as a function of influenza vaccination. The percentage of patients who suffered from moderate and/or severe exacerbations was higher among those vaccinated.

Influenza vaccination had a statistically significant negative (non-protective) crude effect favoring the risk of severe exacerbations: OR 1.20 (95% CI; 1.05--1.37). However, the association was towards the null effect (losing statistical significance) after adjusting for the main confounding variables: ORa 0.93 (95% CI; 0.74--1.18). After restricting to the 2013 influenza epidemic period, a non-significant protective effect against the risk of severe exacerbations was observed: ORa 0.82 (95% CI; 0.58--1.16). After stratifying according to GOLD obstruction severity (GOLD 1--4), a statistically significant negative (non-protective) adjusted effect seemed to be observed in the most severe patients, although statistical significance was not yielded when computing the 2013 influenza epidemic period only ([Table 3](#ijerph-17-04027-t003){ref-type="table"}).

Similar results were obtained restricting the analysis to patients with spirometry confirmed COPD (FEV~1~/FVC \< 0.7), showing a null effect (non-negative, non-positive): ORa 0.97 (95% CI; 0.74--1.27) for the complete year, and ORa 0.81 (95% CI; 0.54--1.22) when the 2013 influenza epidemic period was analyzed ([Supplementary Table S2](#app1-ijerph-17-04027){ref-type="app"}).

A non-significant slightly negative (non-protective) association between influenza seasonal vaccination and COPD moderate exacerbations was found in both the 2013 complete year and in the influenza epidemic period ([Table 4](#ijerph-17-04027-t004){ref-type="table"}).

Similar results were shown in patients with spirometry confirmed COPD (FEV~1~/FVC \< 0.7) ([Supplementary Table S3](#app1-ijerph-17-04027){ref-type="app"}). However, in very severe obstructive GOLD 4 patients, the non-protective effect was higher and statistically significant---ORa 4.54 (95% CI; 1.77--11.67) for the 2013 complete year---and an ORa 3.93 (95% CI; 1.39--11.13) was also obtained after computing the epidemic period only ([Table 4](#ijerph-17-04027-t004){ref-type="table"}), with similar results when restricting to spirometry confirmed COPD patients ([Supplementary Table S3](#app1-ijerph-17-04027){ref-type="app"}).

When the effect was computed as being "exacerbator phenotype or not", that is, suffering from at least two moderate and/or severe exacerbations, an adjusted null effect of vaccination was observed in the overall population, and a negative (non-protective) effect was observed when restricting to very severe GOLD grade 4 patients (ORa 3.72 (95% CI; 1.48--9.33) ([Table 5](#ijerph-17-04027-t005){ref-type="table"})) with similar results when restricting to spirometry confirmed COPD patients ([Supplementary Table S4](#app1-ijerph-17-04027){ref-type="app"}).

4. Discussion {#sec4-ijerph-17-04027}
=============

Our results suggest that influenza vaccination in this concrete campaign (2012/2013) did not have a protective effect on the risk of severe and/or moderate exacerbations in the following year, not even if restricting the analysis to the epidemic influenza period only.

The absence of a preventive effect of seasonal influenza vaccination on moderate exacerbation risk is also supported by previous studies. However, in contrast to our results, no previous studies have shown an increased risk for severe exacerbations in very severe COPD patients after vaccination. In the recently published Spanish \[[@B16-ijerph-17-04027],[@B17-ijerph-17-04027]\] or international studies \[[@B9-ijerph-17-04027],[@B27-ijerph-17-04027]\], a protective effect on risk for severe exacerbations (admission for COPD exacerbation) or all-cause admissions was observed in those receiving seasonal vaccination. The higher protective effect being previously shown for the most severe COPD patients (GOLD 4) \[[@B17-ijerph-17-04027]\] is not supported by our results, given we found the opposite effect.

The influenza strains contributing to epidemics vary annually, and they influence the severity and the length of the epidemic seasonal period. Vaccination impact is supposed to be greater in seasons in which circulating strains match those used in vaccination schemes and lower in poorly matched seasons or so-called mismatched seasons. Influenza activity in Spain in the 2012--2013 season was moderate and was associated with a majority circulation of seasonal influenza B virus with a lower contribution of A(H1N1) virus throughout the pandemic wave \[[@B25-ijerph-17-04027]\]. The circulating viruses were consistent with the strains included in the 2012--2013 season vaccine for the northern hemisphere, except for the B viruses of the Victoria lineage not included in the vaccine recommended for the 2012--2013 season. However, the B viruses of the Victoria lineage circulated in minority, thus a lack of efficacy or mismatched vaccine would not explain the lack of preventive results in our study \[[@B25-ijerph-17-04027]\]. Since the 1996--1997 season, the influenza B virus has circulated predominantly in Spain in just two seasons, 2002--2003 and ten years later in 2012--2013. On the other hand, the 2012--2013 season had a late presentation compared to the previous ones, with an epidemic peak in mid-February. Although the epidemic wave was similar to the previous year, the 2012--2013 season was characterized by a prolonged period of intense flu virus circulation, with a percentage of flu-positive samples remaining above 50% for eleven consecutive weeks \[[@B25-ijerph-17-04027],[@B28-ijerph-17-04027]\]. Regarding the immunogenicity of seasonal influenza vaccines in COPD patients, the seroconversion rates ranged from 34.4 to 61.3% for influenza B in published studies \[[@B29-ijerph-17-04027],[@B30-ijerph-17-04027]\], being lower than the seroconversion rates for A/H1N1 (43 to 80.0%) or A/H3N2 (53.1 to 84.1%). Sero-protection rates for influenza B are also the lowest \[[@B9-ijerph-17-04027]\]. To what extent these peculiarities with respect to previous seasons could explain our results may deserve further attention.

The overall influenza vaccination coverage in the 2012--2013 campaign was 59.6%. This sub-optimal coverage is similar to those generally reported in developed countries, including Spain \[[@B12-ijerph-17-04027],[@B13-ijerph-17-04027],[@B17-ijerph-17-04027],[@B31-ijerph-17-04027]\]. In our study, in line with other authors \[[@B16-ijerph-17-04027],[@B17-ijerph-17-04027],[@B32-ijerph-17-04027]\], we found that patients with several co-morbidities had greater vaccination coverage. It should also be mentioned that vaccination coverage among smokers was lower than among non-smokers, as also reported in other studies \[[@B16-ijerph-17-04027],[@B17-ijerph-17-04027],[@B33-ijerph-17-04027],[@B34-ijerph-17-04027]\].

Vaccination rejection among COPD patients has been attributed to concerns about increased exacerbations or adverse reactions caused by the vaccine itself, which could explain the rejection, even among those with the more severe disease \[[@B13-ijerph-17-04027],[@B16-ijerph-17-04027],[@B34-ijerph-17-04027]\]. However, a greater incidence of exacerbation in the early weeks after vaccination was previously ruled out \[[@B35-ijerph-17-04027],[@B36-ijerph-17-04027]\], and evidence for the safety of the vaccine seems to be conclusive \[[@B9-ijerph-17-04027]\].

Our study has several limitations.

Only a single influenza season (2012--2013) was studied. Looking at other seasons, especially those where recommended vaccine formulations more closely matched circulating virus strains, is needed to fully understand our observations. Similarly, data on serious influenza-related complications in the general population (vaccinated vs. unvaccinated) need to be taken into consideration.

Our study population was selected under the criterion that they should have used respiratory medication during the years of follow-up. This has advantages because it represents a population with active and relevant COPD. On the other hand, it makes it impossible, for example, to study mortality as a dependent variable in relation to influenza vaccination. A differential survival bias based on vaccination status could be a source of selection bias. If unvaccinated people had higher mortality and exacerbated more, the bias would underestimate the preventive effect of the vaccine. If, on the other hand, vaccinated patients, because they have more comorbidities or are older, die and exacerbate more, the bias would be in favor of the protective effect of the influenza vaccine.

The process for classifying record information into the outcome (i.e., moderate or severe exacerbations) was carried out by two physicians who were blinded to the influenza vaccination status of the study subjects. As the classification of the outcome was blinded to the exposed/non-exposed status of the study subjects, any misclassification of the outcome would have been non-differential towards the null association. It could be also a source of explanation for our results.

External validity is one of the main classical limitations of clinical trials, and this problem can also affect observational studies based on small samples \[[@B37-ijerph-17-04027],[@B38-ijerph-17-04027],[@B39-ijerph-17-04027]\]. A major strength of the present study is the inclusion of the entire population, that is, all patients diagnosed with COPD in the Balearic Islands, Spain, (+/− 1.1 million subjects) receiving primary health care and current treatment. This provides a useful COPD cohort representative for real-life care. It is improbable that bias arose through lack of blindness among patients' care providers (they treated the patients blinded retrospectively before the development of the study). Another advantage is that we attempted to obtain the independent effect of flu vaccination in our epidemiological and statistical approach by controlling for potential confounding.

On the other hand, as with many registers and database studies, our data were collected from day-to-day clinical practice registers not specifically designed for the present study, and data collection was not under the researchers' control. Therefore, some unmeasured variables could have confounded the results. Additionally, COPD misdiagnosis could promote a high risk of selection bias. To minimize selection bias, we performed a sensitivity analysis by restricting to only spirometry confirmed COPD cases, and we obtained similar results in this analysis.

5. Conclusions {#sec5-ijerph-17-04027}
==============

The prevalence of influenza vaccination was suboptimal in the Balearic Islands (Spain). In contrast with the available evidence, our results did not support a protective effect of influenza vaccination on the risk of COPD exacerbations during the following year or even during the epidemic influenza season. A majority circulation of seasonal influenza B virus in the 2012--2013 season in Spain, with respect to previous seasons, could potentially explain our results and may deserve further attention. More research into the identification of specific groups where vaccination is effectively preventing exacerbations in COPD patients is needed.
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###### 

Main sociodemographic and clinical variables in relation to influenza vaccination during 2012/2013 seasonal campaign.

                                               Unvaccinated   Vaccinated   Total                                   
  -------------------------------------------- -------------- ------------ -------- --------- -------- ----------- ---------
  **Sex**                                                                                                          
  Women                                        1884           46.4%        2174     53.6%     4058     32.7%       \<0.001
  Men                                          3119           37.4%        5219     62.6%     8338     67.3%       
  **Age**                                                                                                          
  Mean \[SD\]                                  66.56          11.52        71.884   10.08     69.735   11          \<0.001
  **BMI**                                                                                                          
  Mean \[SD\]                                  29.93          6.38         30.17    7.94      30.09    7.42        0.003
  Normal weight (18.5--24.9)                   594            41.1%        850      58.9%     1444     16.90% \*   \<0.001
  Overweight (25--29.9)                        1045           34.1%        2019     65.9%     3064     35.80%      
  Obesity (≥30)                                1381           34.8%        2583     65.2%     3964     46.30%      
  Underweight (\<18.5)                         43             48.9%        45       51.1%     88       1.00%       
  *Missing values*                             *1940*         *50.6%*      *1896*   *49.4%*   *3836*   *30.9%*     
  BMI \> 21                                    2903           35.3%        5311     64.7%     8214     96.00%      \<0.001
  BMI ≤21                                      160            46.2%        186      53.8%     346      4.00%       
  *Missing values*                             *1940*         *50.6%*      *1896*   *49.4%*   *3836*   *30.9%*     
  **Smoking habit**                                                                                                
  Never                                        1233           34.2%        2368     65.8%     3601     32.30% \*   \<0.001
  Former                                       1439           32.9%        2930     67.1%     4369     39.20%      
  Current                                      1735           54.6%        1443     45.4%     3178     28.50%      
  *Missing values*                             *596*          *47.8%*      *652*    *52.2%*   *1248*   *10.1%*     
  **FEV~1~**                                                                                                       
  Mean \[SD\]                                  64.19%         19.56        61.74%   19.79     62.66%   19.74       \<0.001
  **Obstruction severity (FEV~1~)**                                                                                
  GOLD 1 (≥80%)                                467            42.5%        633      57.53%    1100     19.60% \*   \<0.001
  GOLD 2 (≥50--80%)                            1133           37.8%        1862     62.2%     2995     53.40%      
  GOLD 3 (≥30--49.9%)                          449            33.7%        884      66.3%     1333     23.80%      
  GOLD 4 (\<30%)                               64             35.0%        119      65.0%     183      3.30%       
  *Missing values*                             *2890*         *42.6%*      *3895*   *57.4%*   *6785*   *54.7%*     
  **History of moderate exacerbations 2012**                                                                       
  Number of exacerbations, mean \[SD\]         0.7            1            0.84     1.09      0.78     1.06        \<0.001
  None (0 exacerbations)                       2800           43.0%        3714     57.0%     6514     52.5%       
  1 exacerbation                               1332           38.9%        2096     61.1%     3428     27.7%       
  ≥2 exacerbations                             871            35.5%        1583     64.5%     2454     19.8%       
  **Admitted for COPD exacerbation 2012**                                                                          
  Number of COPD admissions, mean \[SD\]       0.08           0.34         0.1      0.39      0.09     0.37        0.003
  None (0 COPD admissions)                     4648           40.7%        6763     59.3%     11411    92.1%       0.01
  1 COPD admission                             292            36.5%        509      63.5%     801      6.5%        
  ≥2 severe exacerbations                      63             34.2%        121      65.8%     184      1.5%        
  **History of overall exacerbations 2012**                                                                        
  Number of exacerbations, mean \[SD\]         0.79           1.15         0.94     1.26      0.88     1.22        \<0.001
  None (0 exacerbations)                       2737           43.1%        3614     56.9%     6351     51.2%       \<0.001
  1 exacerbation                               1254           38.6%        1993     61.4%     3247     26.2%       
  ≥2 exacerbations                             1012           36.2%        1786     63.8%     2798     22.6%       
  **Exacerbator phenotype 2012**                                                                                   
  No                                           3931           41.6%        5514     58.4%     9445     76.2%       \<0.001
  Yes                                          1072           36.3%        1879     63.7%     2951     23.8%       

\* Valid percentage, excluding the missing values. BMI: body mass index, FEV~1~ forced expiratory volume in one second, COPD: chronic obstructive pulmonary disease. GOLD: Global Initiative for Obstructive Pulmonary Disease obstruction grades.
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###### 

Influenza vaccination during the 2012/2013 campaign and exacerbations during the following year.

                                         Unvaccinated   Vaccinated   Total                           
  -------------------------------------- -------------- ------------ ------- ------- ------- ------- ---------
  **Moderate COPD exacerbations 2013**                                                               
  Number of exacerbations.                                                                           
  None (0 exacerbations)                 2750           55.0%        3640    49.2%   6390    51.5%   \<0.001
  1 exacerbation                         1279           25.6%        1943    26.3%   3222    26.0%   
  ≥2 exacerbations                       974            19.5%        1810    24.5%   2784    22.5%   
  **Severe COPD exacerbations 2013**                                                                 
  Number of COPD admissions.                                                                         
  None (0 COPD admissions)               4618           92.3%        6722    90.9%   11340   91.5%   0.003
  1 COPD admission                       320            6.4%         522     7.1%    842     6.8%    
  ≥2 COPD admissions                     65             1.3%         149     2.0%    214     1.7%    
  **Overall COPD exacerbations 2013**                                                                
  Number of exacerbations.                                                                           
  None (0 exacerbations)                 2701           54.0%        3564    48.2%   6265    50.5%   \<0.001
  1 exacerbation                         1187           23.7%        1815    24.6%   3002    24.2%   
  ≥2 exacerbations                       1115           22.3%        2014    27.2%   3129    25.2%   
  **Exacerbator phenotype 2013**                                                                     
  No                                     3842           76.8%        5311    71.8%   9153    73.8%   \<0.001
  Yes                                    1161           23.2%        2082    28.2%   3243    26.2%   

ijerph-17-04027-t003_Table 3

###### 

Crude and adjusted associations between "History of Influenza Vaccination during 2012--2013 campaign" and risk of "Admission due to COPD Exacerbation" in all patients with a diagnosis of COPD by obstruction severity during the complete year and the epidemic period.

                            Severe Exacerbations (Admitted for COPD Exacerbation)                                                                                                
  ------------------------- ------------------------------------------------------- ----- ------ -------------- ------ --------------- ------ ----- ------ -------------- ------ --------------
  ***All COPD***                                                                                                                                                                 
  ***(N = 12,396)***                                                                                                                                                             
  *Unvaccinated*            4618                                                    385   1      \--            1      \--             4846   157   1      \--            1      \--
  *Vaccinated*              6722                                                    671   1.20   (1.05--1.37)   0.93   (0.74--1.18)    7151   242   1.05   (0.85--1.28)   0.82   (0.58--1.16)
  ***GOLD 1 (N = 1100)***                                                                                                                                                        
  *Unvaccinated*            448                                                     19    1      \--            1      \--             461    6     1      \--            1      \--
  *Vaccinated*              603                                                     30    1.17   (0.65--2.11)   0.87   (0.45--1.69)    623    10    1.23   (0.45--3.42)   0.94   (0.31--2.84)
  ***GOLD 2 (N = 2995)***                                                                                                                                                        
  *Unvaccinated*            1050                                                    83    1      \--            1      \--             1095   38    1      \--            1      \--
  *Vaccinated*              1741                                                    121   0.88   (0.66--1.18)   0.72   (0.52--1.00)    1813   49    0.78   0.51--1.20     0.71   0.44--1.16)
  ***GOLD 3 (N = 1333)***                                                                                                                                                        
  *Unvaccinated*            398                                                     51    1      \--            1      \--             428    21    1      \--            1      \--
  *Vaccinated*              757                                                     127   1.31   (0.93--1.85)   1.07   (0.71--1.61)    842    42    1.02   (0.59--1.74)   0.78   (0.42--1.44)
  ***GOLD 4 (N = 183)***                                                                                                                                                         
  *Unvaccinated*            55                                                      9     1      \--            1      \--             60     4     1      \--            1      \--
  *Vaccinated*              91                                                      28    1.88   (0.83--4.28)   6.09   (1.77--20.97)   109    10    1.38   (0.41--4.58)   2.17   0.40--11.73

OR: crude odds ratio. ORa: odds ratio adjusted for age (continuous variable), gender, concomitant asthma diagnosis, smoking status (ordinal variable: non-smoker, former smoker, current smoker), number of moderate exacerbations the previous year, number of severe exacerbations the previous year, and the following comorbidities: heart failure, atrial fibrillation, cor pulmonale, anxiety disorder, osteoporosis, allergic rhinitis, gastroesophageal reflux disease, and diabetes. COPD obstruction severity: GOLD 1: mild; GOLD 2 moderate; GOLD 3: severe; GOLD 4 very severe.
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###### 

Crude and adjusted associations between "History of Influenza Vaccination" and risk of moderate COPD Exacerbations" in all patients with a diagnosis of COPD by obstruction severity during the complete year and the epidemic period.

                                             Moderate Exacerbations                                                                                                  
  ------------------------------------------ ------------------------ ------ ------ -------------- ------ --------------- ------ ------ ------ -------------- ------ --------------
  ***Influenza Vaccination (N = 12,396)***                                                                                                                           
  *Unvaccinated*                             2750                     2253   1      \--            1      \--             3891   1112   1      \--            1      \--
  *Vaccinated*                               3640                     3753   1.26   (1.17--1.35)   1.10   (0.97--1.24)    5460   1933   1.24   (1.14--1.35)   1.11   (0.96--1.28)
  ***GOLD 1 (N = 1100)***                                                                                                                                            
  *Unvaccinated*                             285                      182    1      \--            1      \--             383    84     1      \--            1      \--
  *Vaccinated*                               329                      304    1.45   (1.14--1.84)   1.21   (0.91--1.61)    475    158    1.52   (1.13--2.04)   1.33   (0.95--1.86)
  ***GOLD 2 (N = 2995)***                                                                                                                                            
  *Unvaccinated*                             648                      485    1      \--            1      \--             892    241    1      \--            1      \--
  *Vaccinated*                               964                      898    1.25   (1.07--1.44)   1.11   (0.93--1.31)    1404   458    1.21   (1.01--1.44)   1.05   (0.86--1.28)
  ***GOLD 3 (N = 1333)***                                                                                                                                            
  *Unvaccinated*                             203                      246    1      \--            1      \--             323    126    1      \--            1      \--
  *Vaccinated*                               388                      496    1.06   (0.84--1.33)   0.84   (0.65--1.09)    606    278    1.18   (0.92--1.51)   1.00   (0.75--1.33)
  ***GOLD 4 (N = 183)***                                                                                                                                             
  *Unvaccinated*                             37                       27     1      \--            1      \--             47     17     1      \--            1      \--
  *Vaccinated*                               45                       74     2.25   (1.21--4.19)   4.54   (1.77--11.67)   77     42     1.51   (0.77--2.95)   3.93   1.39--11.13

OR: crude odds ratio. ORa: odds ratio adjusted for age (continuous variable), gender, concomitant asthma diagnosis, smoking status (ordinal variable: non-smoker, former smoker, current smoker), number of moderate exacerbations the previous year, number of severe exacerbations the previous year, and the following comorbidities: heart failure, atrial fibrillation, cor pulmonale, anxiety disorder, osteoporosis, allergic rhinitis, gastroesophageal reflux disease, and diabetes. COPD obstruction severity: GOLD 1: mild; GOLD 2 moderate; GOLD 3: severe; GOLD 4 very severe.
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###### 

Crude and adjusted associations between "History of Influenza Vaccination" and risk of being "Frequent exacerbator phenotype" the following year in all patients with a diagnosis of COPD by obstruction severity.

                                                2013 Frequent Exacerbator Phenotype                                       
  --------------------------------------------- ------------------------------------- ------ ------ -------------- ------ --------------
  Influenza Vaccination (2012--2013 Campaign)                                                                             
  Total (*N*= 12,396)                                                                                                     
  Unvaccinated                                  3842                                  1161   1      \--            1      \--
  Vaccinated                                    5311                                  2082   1.30   (1.19--1.41)   1.02   (0.88--1.19)
  GOLD 1 (*N* = 1100)                                                                                                     
  Unvaccinated                                  384                                   83     1      \--            1      \--
  Vaccinated                                    488                                   145    1.38   (1.02--1.86)   1.15   (0.80--1.63)
  GOLD 2 (*N* = 2995)                                                                                                     
  Unvaccinated                                  876                                   257    1      \--            1      \--
  Vaccinated                                    1409                                  453    1.10   (0.92--1.31)   0.91   (0.74--1.12)
  GOLD 3 (*N* = 1333)                                                                                                     
  Unvaccinated                                  315                                   134    1      \--            1      \--
  Vaccinated                                    569                                   315    1.30   (1.02--1.66)   1.03   (0.77--1.39)
  GOLD 4 (*N* = 183)                                                                                                      
  Unvaccinated                                  41                                    23     1      \--            1      \--
  Vaccinated                                    65                                    54     1.48   (0.79--2.77)   3.72   (1.48--9.33)

OR: crude odds ratio. ORa: odds ratio adjusted for age (continuous variable), gender, concomitant asthma diagnosis, smoking status (ordinal variable: non-smoker, former smoker, current smoker), number of moderate exacerbations the previous year, number of severe exacerbations the previous year, and the following comorbidities: heart failure, atrial fibrillation, cor pulmonale, anxiety disorder, osteoporosis, allergic rhinitis, gastroesophageal reflux disease, and diabetes. COPD obstruction severity: GOLD 1: mild; GOLD 2 moderate; GOLD 3: severe; GOLD 4 very severe.
